Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Inorganic Nanoparticles for Cancer Immunotherapy and Diagnosis
share announcement

Inorganic Nanoparticles for Cancer Immunotherapy and Diagnosis

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (15 November 2021) | Viewed by 8029

Special Issue Editor

Prof. Nam-Hyuk Cho

E-Mail
Guest Editor
1. Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul 03080, Korea
2. Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea
Interests: nanocomposites; vaccine; cancer; immunotherapy; host-pathogen interactions

Special Issue Information

Dear Colleagues,

The application of nanomaterials has enormously contributed to the technical advances in various biomedical fields. This Special Issue is focused on advanced platforms and technologies using inorganic nanomaterials for cancer immunotherapy and in vivo imaging to achieve enhanced therapeutic outcomes and diagnostic monitoring. Recent advances in nanotechnologies based on inorganic metals, carbon nanostructures, or others could be covered by the Special Issue. We believe your contribution, based on your expertise, would be a valuable addition to our collection.

Prof. Nam-Hyuk Cho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inorganic nanoparticles
  • nanocomposites
  • cancer
  • immunotherapy
  • in vivo imaging
  • diagnosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

29 pages, 4510 KiB  
Review
Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting
by Laura Sanz-Ortega, José Manuel Rojas and Domingo F. Barber
Pharmaceutics 2020, 12(9), 812; https://doi.org/10.3390/pharmaceutics12090812 - 27 Aug 2020
Cited by 13 | Viewed by 3527
Abstract
Adoptive cell transfer therapy is a promising anti-tumor immunotherapy in which effector immune cells are transferred to patients to treat tumors. However, one of its main limitations is the inefficient trafficking of inoculated effector cells to the tumor site and the small percentage [...] Read more.
Adoptive cell transfer therapy is a promising anti-tumor immunotherapy in which effector immune cells are transferred to patients to treat tumors. However, one of its main limitations is the inefficient trafficking of inoculated effector cells to the tumor site and the small percentage of effector cells that remain activated when reaching the tumor. Multiple strategies have been attempted to improve the entry of effector cells into the tumor environment, often based on tumor types. It would be, however, interesting to develop a more general approach, to improve and facilitate the migration of specific activated effector lymphoid cells to any tumor type. We and others have recently demonstrated the potential for adoptive cell transfer therapy of the combined use of magnetic nanoparticle-loaded lymphoid effector cells together with the application of an external magnetic field to promote the accumulation and retention of lymphoid cells in specific body locations. The aim of this review is to summarize and highlight the recent findings in the field of magnetic accumulation and retention of effector cells in tumors after adoptive transfer, and to discuss the possibility of using this approach for tumor targeting with chimeric antigen receptor (CAR) T-cells. Full article
(This article belongs to the Special Issue Inorganic Nanoparticles for Cancer Immunotherapy and Diagnosis)
►▼ Show Figures

Figure 1

19 pages, 2476 KiB  
Review
Nanoparticle-Mediated Therapeutic Application for Modulation of Lysosomal Ion Channels and Functions
by Dongun Lee and Jeong Hee Hong
Pharmaceutics 2020, 12(3), 217; https://doi.org/10.3390/pharmaceutics12030217 - 2 Mar 2020
Cited by 15 | Viewed by 4080
Abstract
Applications of nanoparticles in various fields have been addressed. Nanomaterials serve as carriers for transporting conventional drugs or proteins through lysosomes to various cellular targets. The basic function of lysosomes is to trigger degradation of proteins and lipids. Understanding of lysosomal functions is [...] Read more.
Applications of nanoparticles in various fields have been addressed. Nanomaterials serve as carriers for transporting conventional drugs or proteins through lysosomes to various cellular targets. The basic function of lysosomes is to trigger degradation of proteins and lipids. Understanding of lysosomal functions is essential for enhancing the efficacy of nanoparticles-mediated therapy and reducing the malfunctions of cellular metabolism. The lysosomal function is modulated by the movement of ions through various ion channels. Thus, in this review, we have focused on the recruited ion channels for lysosomal function, to understand the lysosomal modulation through the nanoparticles and its applications. In the future, lysosomal channels-based targets will expand the therapeutic application of nanoparticles-associated drugs. Full article
(This article belongs to the Special Issue Inorganic Nanoparticles for Cancer Immunotherapy and Diagnosis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop